Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Thomas, Buttgereit"'
Autor:
Thomas Buttgereit, Carolina Vera Ayala, Seda Aykanat, Karsten Weller, Annika Gutsche, Marcus Maurer, Markus Magerl
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionLanadelumab is a first-line long-term prophylaxis (LTP) in hereditary angioedema (HAE). Real-life data on its long-term efficacy and safety are limited. It is unknown whether patients using lanadelumab need short-term prophylaxis (STP).Ob
Externí odkaz:
https://doaj.org/article/7536b60b93bf481ea32a454fc35cf1e6
Autor:
Lauré M. Fijen, Carolina Vera, Thomas Buttgereit, Hanna Bonnekoh, Marcus Maurer, Markus Magerl, Karsten Weller
Publikováno v:
Clinical and Translational Allergy, Vol 13, Iss 9, Pp n/a-n/a (2023)
Abstract Background The Angioedema Control Test (AECT) is a patient‐reported outcome measure developed and validated for the assessment of disease control in patients with recurrent angioedema. Its sensitivity to change and minimal clinically impor
Externí odkaz:
https://doaj.org/article/e4a1c1f171b74b6b9c1e23c3723499c5
Autor:
Marcus Maurer, Thomas Buttgereit, Markus Magerl, Kathrin Schön, Zsusanna Balla, Henriette Farkas
Publikováno v:
Clinical and Translational Allergy, Vol 13, Iss 9, Pp n/a-n/a (2023)
Abstract Background The coronavirus disease pandemic and its containing measures have caused concerns for patients with hereditary angioedema (HAE) and their treating physicians. Both faced challenges surrounding interaction, and communication had to
Externí odkaz:
https://doaj.org/article/af02a9b6caa94b2c9da42740a4052139
Autor:
Thomas Buttgereit, Lauré M. Fijen, Carolina Vera, Karl-Christian Bergmann, Marcus Maurer, Markus Magerl
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Hereditary angiodema with normal C1 inhibitor and unknown mutation (HAE-nC1INH-UNK), an exceedingly rare subtype of HAE, appears to be often diagnosed in patients who do not have this condition, but have mast cell-mediated angioedema. Here, we report
Externí odkaz:
https://doaj.org/article/54b0eab98afc498dbe08935f9624c88b
Autor:
Yuling Chen, Yuanchun Ye, Pierre-Louis Krauß, Pelle Löwe, Moritz Pfeiffenberger, Alexandra Damerau, Lisa Ehlers, Thomas Buttgereit, Paula Hoff, Frank Buttgereit, Timo Gaber
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Cellular metabolism modulates effector functions in human CD4+ T (Th) cells by providing energy and building blocks. Conversely, cellular metabolic responses are modulated by various influences, e.g., age. Thus, we hypothesized that metabolic reprogr
Externí odkaz:
https://doaj.org/article/d4042bd325db4c8ea4e6be1b87aa2087
Publikováno v:
JAAD Case Reports, Vol 15, Iss , Pp 36-38 (2021)
Externí odkaz:
https://doaj.org/article/8856278380a24cd2999a99945b7f866d
Autor:
Werner Stenzel, Udo Schneider, Robert Biesen, Gerd R Burmester, Falk Hiepe, Tilmann Kallinich, Martin Krusche, Christian Meisel, Nadine Unterwalder, Jens Klotsche, Thomas Rose, Akinori Uruha, Manuel Graf, Sae Lim von Stuckrad, Lydia Zorn-Pauly, Thomas Buttgereit
Publikováno v:
RMD Open, Vol 8, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/64c804afb42a466d90d916d7a69dde0e
Autor:
Pierre-Louis Krauss, Moritz Pfeiffenberger, Alexandra Damerau, Thomas Buttgereit, Yuling Chen, Timo Gaber, Frank Buttgereit
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
At sites of inflammation, monocytes carry out specific immune functions while facing challenging metabolic restrictions. Here, we investigated the potential of human monocytes to adapt to conditions of gradually inhibited oxidative phosphorylation (O
Externí odkaz:
https://doaj.org/article/0de51965945d4126b3318f16b711568e
Autor:
Thomas Buttgereit, Moritz Pfeiffenberger, Stefan Frischbutter, Pierre-Louis Krauß, Yuling Chen, Marcus Maurer, Frank Buttgereit, Timo Gaber
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 19, p 11591 (2022)
The mechanisms of mast cell (MC) degranulation and MC-driven skin symptoms are well-described. In contrast, data about the role of mitochondrial respiration for immune functions of human skin MCs are lacking. Oxygen consumption rate (OCR) in primary
Externí odkaz:
https://doaj.org/article/f9ee1f6cfc9e4cb5b6fa976463206927
Autor:
Edgar Wiebe, Dörte Huscher, Désireé Schaumburg, Andriko Palmowski, Sandra Hermann, Thomas Buttgereit, Robert Biesen, Gerd-Rüdiger Burmester, Yannick Palmowski, Maarten Boers, John H Stone, Christian Dejaco, Frank Buttgereit
Publikováno v:
Annals of the Rheumatic Diseases, 81(9):heartjnl-2022-222339, 1313-1322. BMJ Publishing Group
Wiebe, E, Huscher, D R, Schaumburg, D S, Palmowski, A, Hermann, S, Buttgereit, T, Biesen, R, Burmester, G-R D, Palmowski, Y, Boers, M, Stone, J H, Dejaco, C & Buttgereit, F 2022, ' Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease ', Annals of the Rheumatic Diseases, vol. 81, no. 9, heartjnl-2022-222339, pp. 1313-1322 . https://doi.org/10.1136/annrheumdis-2022-222339
Wiebe, E, Huscher, D R, Schaumburg, D S, Palmowski, A, Hermann, S, Buttgereit, T, Biesen, R, Burmester, G-R D, Palmowski, Y, Boers, M, Stone, J H, Dejaco, C & Buttgereit, F 2022, ' Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease ', Annals of the Rheumatic Diseases, vol. 81, no. 9, heartjnl-2022-222339, pp. 1313-1322 . https://doi.org/10.1136/annrheumdis-2022-222339
ObjectivesInflammatory rheumatic and musculoskeletal diseases (iRMDs) are associated with increased systemic bone loss that is mediated by chronic inflammation, treatment with glucocorticoids (GCs) and other factors. Our objective was to analyse the